Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Polymyalgia Rheumatica (PMR).

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage trial.

Eli Lilly (NYSE:LLY) announced on Wednesday an agreement with Egypt-based EVA Pharma to license certain manufacturing ...